Anticorps H1N1 hemagglutinine Anti - saisonnier produit en lapin, anticorps isolé affinité, solution aqueuse tamponnée

Non disponible en dehors du Royaume-Uni et de l'Irlande

Disclaimer

Unless otherwise stated in our catalog or other company documentation accompanying the product(s), our products are intended for research use only and are not to be used for any other purpose, which includes but is not limited to, unauthorized commercial uses, in vitro diagnostic uses, ex vivo or in vivo therapeutic uses or any type of consumption or application to humans or animals.

Features and Benefits

Evaluate our antibodies with complete peace of mind. If the antibody does not perform in your application, we will issue a full credit or replacement antibody. Learn more.

Immunogen

Hemagglutinin antibody was raised against a synthetic peptide from the Hemagglutinin protein. The peptide sequence is unique from the peptide sequence for product SAB3500058 and SAB3500062. This antibody is a cognate pair with antibody SAB3500061.

Linkage

The action of this antibody can be blocked using blocking peptide SBP3500060.

Physical form

Supplied at approx. 1 mg/mL in phosphate buffered saline containing 0.02% sodium azide.

Target description

Influenza A virus is a major public health threat, killing more than 30,000 people per year in the USA (1). In early 2009, a novel swine-origin influenza A (H1N1) virus was identified in specimens obtained from patients in Mexico and the United States (2). The virus spread quickly around the world and on June 11, 2009, the World Health Organization declared it a pandemic (3). Influenza A virus has one of sixteen possible Hemagglutinin (HA) surface proteins and one of nine possible neuraminidase (NA) surface proteins. The Hemagglutinin protein facilitates viral attachment while neuraminidase is involved in viral release. These proteins also elicit immune responses that prevent infection or independently reduce viral replication. The genetic make-up of this swine flu virus is unlike any other: it is an H1N1 strain that combines a triple assortment first identified in 1998 including human, swine, and avian influenza with two new pig H3N2 virus genes from Eurasia, themselves of recent human origin (4). The distinct antigenic properties of the new swine virus compared with seasonal influenza A (H1N1) virus suggest that human immunity against new swine influenza virus is limited, although the age distribution of reported cases suggests some degree of protection in older age groups (5). This antibody is specific for the seasonal H1N1 influenza Hemagglutinin and will not recognize the corresponding Hemagglutinin sequence from the swine-origin H1N1 influenza (A/California/14/2009 (H1N1)).